Are tablets weaker than injections?

Not as a rule. Oral semaglutide's 16.6% at 64 weeks under adherence in OASIS 4 is close to injectable semaglutide's 14.9% at 68 weeks on 2.4 mg in STEP 1, and both sit below tirzepatide's 22.5% at 72 weeks on 15 mg in SURMOUNT-1. The format is not what separates those results.

Are the pills less likely to go into shortage?

Manufacturing points that way for one of them. Peptide production was the bottleneck behind the injectable GLP-1 shortages, and orforglipron is a small molecule made by a different route. Oral semaglutide is still a peptide, so it depends on the same production the injectables do.

Can I move from my injection to one of these and keep the weight off?

There is phase 3 evidence on switching from injectable incretin therapy to oral orforglipron, and it is emerging rather than settled. It is set out with its caveats on the maintenance page. Nothing comparable has been published for switching to oral semaglutide.

Orforglipron vs Oral Semaglutide, Compared

What this page establishes

Oral semaglutide 25 mg was FDA-approved 22 December 2025 for weight reduction, long-term maintenance and reduction of MACE risk.
Orforglipron 36 mg gave 12.4% (efficacy estimand) / 9.6% (treatment-regimen estimand) at 72 weeks in ATTAIN-1.
Orforglipron is taken without food or water restrictions; oral semaglutide is a peptide tablet with absorption requirements.
SELECT's 20% MACE reduction was obtained at 2.4 mg semaglutide over a median 39.8 months; there is no low-dose cardiovascular outcome trial.

Quick answers

Are tablets weaker than injections?
Not as a rule. Oral semaglutide's 16.6% at 64 weeks under adherence in OASIS 4 is close to injectable semaglutide's 14.9% at 68 weeks on 2.4 mg in STEP 1, and both sit below tirzepatide's 22.5% at 72 weeks on 15 mg in SURMOUNT-1.
Read the full answer
The format is not what separates those results.
Are the pills less likely to go into shortage?
Manufacturing points that way for one of them. Peptide production was the bottleneck behind the injectable GLP-1 shortages, and orforglipron is a small molecule made by a different route.
Read the full answer
Oral semaglutide is still a peptide, so it depends on the same production the injectables do.
Can I move from my injection to one of these and keep the weight off?
There is phase 3 evidence on switching from injectable incretin therapy to oral orforglipron, and it is emerging rather than settled.
Read the full answer
It is set out with its caveats on the maintenance page. Nothing comparable has been published for switching to oral semaglutide.

There are now two approved GLP-1 tablets for weight management, and they are more different than they look. Oral semaglutide 25 mg is a peptide in a tablet, approved 22 December 2025, carrying a cardiovascular indication and reporting 16.6% weight loss at 64 weeks under adherence. Orforglipron (Foundayo) is a small molecule with no food or water restrictions, approved 1 April 2026, at 12.4% over 72 weeks on the comparable estimand. No head-to-head trial has been published, so every comparison below is indirect.

Two pills, two different kinds of molecule

Oral semaglutide is the same peptide as injectable semaglutide, formulated so that enough of it survives the stomach to be absorbed. That formulation is the reason the label carries administration requirements.

Orforglipron is not a peptide. It is a small molecule that happens to activate the same receptor, so it needs no absorption scaffolding and no timing rules. The difference also runs through manufacturing: peptide production is the bottleneck that put injectable GLP-1s into shortage, and small-molecule production is not.

Side by side

These figures come from separate trials in separate populations. They are not commensurable, and the table exists to show what each trial measured rather than to rank the drugs.

	Oral semaglutide 25 mg	Orforglipron
Molecule type	Peptide, formulated for oral absorption	Small molecule, non-peptide
Approval	FDA, 22 December 2025	FDA, 1 April 2026 (Foundayo, NDA 220934)
Key trial	OASIS 4, n=307, 64 weeks	ATTAIN-1, 72 weeks, ATTAIN programme >4,500 participants
Weight loss	16.6% under adherence at 64 weeks	12.4% efficacy estimand / 9.6% treatment-regimen estimand at 72 weeks, 36 mg
Responder detail	About one in three lost 20% or more	59.6% lost 10% or more, 39.6% lost 15% or more (efficacy estimand)
Administration	Absorption requirements set out in the label	No food or water restrictions
Indication scope	Weight reduction, long-term maintenance, MACE risk reduction	Weight management (check current label)
Head-to-head data	None published	None published

What each trial actually measured

OASIS 4 randomised 307 adults over 64 weeks and reported 16.6% mean weight loss under adherence, a sponsor-reported figure, with roughly one in three participants losing 20% or more. ATTAIN-1 ran 72 weeks and reported both estimands for the 36 mg dose: 12.4% under adherence and 9.6% counting everyone randomised.

Comparing 16.6% to 12.4% is the closest like-for-like available, because both describe the effect under adherence. It is still two trials, two populations and two sample sizes, one of which is roughly fifteen times the other across its programme. Comparing 16.6% to 9.6% is a mistake, because those are different estimands answering different questions.

Match the estimand before you compare The single most common error in GLP-1 comparison content is putting an efficacy-estimand number from one trial next to a treatment-regimen number from another. That comparison can invent a gap of several percentage points that has nothing to do with the drugs.

Administration, and why it is not a footnote

Oral semaglutide's absorption requirements have to be followed every day for as long as someone takes the drug. Orforglipron was approved without food or water restrictions.

Adherence is where trial results and real-world results diverge, and a daily rule is a daily opportunity to break it. That is exactly why OASIS 4's 16.6% carries the phrase under adherence: it is the number for people who took it correctly.

Indication scope

Oral semaglutide 25 mg was approved for weight reduction, long-term weight maintenance and reduction of major adverse cardiovascular event risk. That third element is the one people overlook, and it rests on the semaglutide cardiovascular evidence base, including SELECT, which enrolled 17,604 participants and showed a 20% MACE reduction over a median 39.8 months on 2.4 mg injectable.

Orforglipron's approval was for weight management. Cardiovascular outcome data for it are still accumulating. Indications do not transfer across a drug class, so the current label is the only source for what each one covers.

What has not been compared

No randomised head-to-head trial of the two oral agents has been published. Nothing in the available evidence establishes which produces more weight loss in the same population, which is better tolerated, or which holds weight off longer.

Indirect comparison is a legitimate thing to do carefully and a poor basis for a clinical decision. The choice between them turns on indication scope, administration, tolerability, cost and supply, and those are questions for the person prescribing.

Not medical advice Educational content only. Approval dates cited here come from the FDA records for each product, and label scope should be confirmed against the current FDA labels. Which medicine suits you is a decision for a licensed prescriber who knows your history.

The evidence, one row per claim

Claim	Tier	Source
Oral semaglutide 25 mg was FDA-approved 22 December 2025 for weight reduction, long-term maintenance and reduction of MACE risk.	established	Drugs@FDA record for NDA 218316 (Wegovy tablets, Novo Nordisk) via openFDA
OASIS 4 (307 adults, 64 weeks) reported 16.6% mean weight loss under adherence, with one in three losing >=20%.	weak evidence	Applied Clinical Trials (not confirmed against a primary source, 2026-08-23)
Orforglipron 36 mg gave 12.4% (efficacy estimand) / 9.6% (treatment-regimen estimand) at 72 weeks in ATTAIN-1.	established	ClinicalTrials.gov posted results for ATTAIN-1 (NCT05869903), first posted 14 August 2026
Orforglipron is taken without food or water restrictions; oral semaglutide is a peptide tablet with absorption requirements.	established	MedCentral
No head-to-head randomised comparison of the two oral agents has been published; all comparison is indirect.	emerging	AJMC (absence of head-to-head)
SELECT's 20% MACE reduction was obtained at 2.4 mg semaglutide over a median 39.8 months; there is no low-dose cardiovascular outcome trial.	established	ACC / SELECT
Semaglutide injectable: 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg weekly, 4 weeks per step, 2.4 mg maintenance; 14.9% mean loss at 68 weeks (STEP 1).	established	STEP 1
Tirzepatide: 2.5 mg initiation then 5 / 10 / 15 mg weekly maintenance; 16.0% / (10 mg intermediate) / 22.5% mean loss at 72 weeks (SURMOUNT-1).	established	Eli Lilly / NEJM

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 8 sourced claims below the fold, each with the document it came from.

Sources consulted: Drugs@FDA record for NDA 218316, Applied Clinical Trials, ClinicalTrials.gov posted results for ATTAIN-1, MedCentral, AJMC and 3 more.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.

Oral GLP-1 Options Compared: Orforglipron vs Oral Semaglutide 25 mg